Drug intelligence / Profile preview

DV700P-RNA

Development stage: Phase 1
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

DV700P-RNA is an investigational RNA-based immunostimulant vaccine candidate developed for the prevention of HIV infection. It is designed to induce an immune response against the V3 region of the HIV envelope, aiming to stimulate protective immunity in healthy adults. The drug is currently being evaluated in first-in-human, phase 1 clinical trials to assess its safety and immunogenicity[3][8][10]. The development was initiated by the National Institute of Allergy & Infectious Diseases (NIAID)[1][8].

Brand names: DV700P-RNADV-700P-RNADV 700P-RNA
Other names: DV700P-RNADV-700P-RNADV 700P-RNA

Targets

V3 loop (HIV-1 gp120 V3 loop)

Beyond the preview

Go deeper on DV700P-RNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DV700P-RNA.

Explore the full profile